Inmune Bio (INMB) Operating Expenses (2018 - 2026)
Inmune Bio (INMB) posted Operating Expenses of $5.8 million for Q1 2026, up 6.17% sequentially from $5.5 million in Q4 2025, and down 41.62% YoY from $10.0 million in Q1 2025.
Inmune Bio (INMB) Operating Expenses (2018 - 2026) Analysis & Trends
Inmune Bio has reported Operating Expenses for 9 years, with the latest figure at $5.8 million in Q1 2026.
- Quarterly Operating Expenses fell 41.62% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.3 million (up 4.13% YoY) and the FY2025 annual result came in at $47.4 million, up 11.22% from the prior year.
- Operating Expenses rose to $5.8 million in Q1 2026 per INMB's latest filing, from $5.5 million in the prior quarter.
- Over five years, Operating Expenses peaked at $24.6 million in Q2 2025 and troughed at $5.5 million in Q4 2025.
- A 5-year average of $8.9 million and a median of $7.5 million in 2022 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 149.07% in 2025, down 42.18% in 2025.
- Over 5 years, Operating Expenses stood at $5.7 million in 2022, then surged by 46.49% to $8.4 million in 2023, then rose by 12.61% to $9.5 million in 2024, then slumped by 42.18% to $5.5 million in 2025, then rose by 6.17% to $5.8 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $5.8 million, $5.5 million, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.99 Bn | 132.14 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.80 Bn | 78.80 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.38 Bn | 60.19 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 60.70 Bn | 55.56 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.21 Bn | 26.37 Bn | - | 541.02 Mn |
| 10 | Inmune Bio | 60.39 Mn | 41.98 Mn | - | 1.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.48 Mn |
| Mar 31, 2026 | 5.81 Mn |
| Dec 31, 2025 | 5.47 Mn |
| Sep 30, 2025 | 7.43 Mn |
| Jun 30, 2025 | 24.57 Mn |
| Mar 31, 2025 | 9.96 Mn |
| Dec 31, 2024 | 9.47 Mn |
| Sep 30, 2024 | 12.29 Mn |
| Jun 30, 2024 | 9.87 Mn |
| Mar 31, 2024 | 11.03 Mn |
| Dec 31, 2023 | 8.41 Mn |
| Sep 30, 2023 | 8.57 Mn |
| Jun 30, 2023 | 6.46 Mn |
| Mar 31, 2023 | 6.46 Mn |
| Dec 31, 2022 | 5.74 Mn |
| Sep 30, 2022 | 7.54 Mn |
| Jun 30, 2022 | 6.40 Mn |
| Mar 31, 2022 | 6.64 Mn |
| Dec 31, 2021 | 9.19 Mn |
| Sep 30, 2021 | 9.04 Mn |